Healthcare
Live Price
Offline$31.00
+2.45% today
1Y Change
+166.70%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stoke Therapeutics, Inc. (STOK) is a Healthcare stock with a market cap of $1.96B and listed on NASDAQ. The stock last traded around $31.00 and up 166.7% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +404.5%, EPS growth of +92.7%, a dividend yield of 0.0%. What stands out right now is revenue +404.5%, EPS +92.7%, free cash flow +151.6% with operating margin -11.2% and ROIC -5.7%. Valuation already assumes a fairly strong business story at price/sales 10.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STOK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STOK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STOK Max Drawdown
-37.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STOK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$85.8M
+15.1% YoY
Free Cash Flow
-$68.1M
-90.1% YoY
Revenue Growth
+404.5%
EPS Growth
+92.7%
Gross Margin
98.9%
Net Margin
-3.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 184M | 37M | 9M | 12M | 0 |
| Gross Profit | 184M | 37M | 9M | 12M | 0 |
| Operating Income | -21M | -101M | -115M | -104M | -86M |
| EBITDA | -19M | -99M | -112M | -103M | -85M |
| Net Income | -7M | -89M | -105M | -101M | -86M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84M | 128M | 191M | 114M | 145M |
| Total Assets | 418M | 272M | 228M | 256M | 239M |
| Total Liabilities | 66M | 43M | 69M | 71M | 21M |
| Shareholder Equity | 352M | 229M | 160M | 185M | 218M |
| Total Debt | 0 | 2M | 2M | 2M | 2M |
| Net Debt | -84M | -126M | -189M | -111M | -143M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
67M
-110.0% YoY
Capital Expenditures
1M
+69.7% YoY
Free Cash Flow
68M
-90.1% YoY
Key ratios
Gross Margin
98.9%
Operating Margin
-11.2%
Net Margin
-3.7%
ROE
-2.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.